Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Market Cap	32.18B
Revenue (ttm)	37.25M
Net Income (ttm)	-628.59M
Shares Out	168.46M
EPS (ttm)	-3.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	357,777
Average Volume	692,216
Open	192.50
Previous Close	188.50
Day's Range	188.50 - 194.50
52-Week Range	122.00 - 400.00
Beta	-0.10
RSI	72.02
Earnings Date	Aug 8, 2025

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 43
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.